Do you suffer from moderate to severe Ulcerative Colitis?

You may be eligible to participate in a clinical study for ulcerative colitis treatment.

Do you suffer from moderate to severe Ulcerative Colitis? You may be eligible to participate in a clinical study for ulcerative colitis treatment.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Ulcerative Colitis Clinical Trial in Long Beach CA
NCT02958865 | Phase 2 | Interventional

What you may receive

Compensation of 90 per visit (11-15) + 50 travel

Study related treatment at no cost

Travel expenses covered

No insurance needed

Pfizer
Sponsored by
Pfizer

Do you suffer from moderate to severe Ulcerative Colitis?

You may be eligible to participate in a clinical study for ulcerative colitis treatment.

Do you suffer from moderate to severe Ulcerative Colitis? You may be eligible to participate in a clinical study for ulcerative colitis treatment.

Completed

Male & Female

18 - 75

Years old

This study has recruited 319 Participants

This Clinical trial is examining new treatment options that could help patients with moderate to severe Ulcerative Colitis stay in remission for longer periods of time.

Why should I participate?

Ulcerative colitis (UC) is a chronic disease that can seriously affect quality of life for those who suffer from this painful condition. Defined by inflammation and ulceration of the colon, many people with UC experience symptoms of rectal bleeding, lower abdominal pain and diarrhea. Symptoms of UC may disappear during periods of remission that can last days, weeks or even years. The goal of medication is to keep people in remission longer.

A clinical research study is underway to evaluate the safety and effectiveness of two oral investigational medications for UC. The study is planning to enroll 360 adults in the US, Canada, Europe, Asia and the Middle East, aged 18 to 70 years of age, who have moderate to severe UC with inadequate response of symptoms from at least one standard UC treatment.

What's involved?

Participants in the study will be asked to attend 11 study clinic visits over a 10-month period including: a screening visit, a baseline visit, 8 study dosing and evaluation visits and a follow-up visit. Participants will receive investigational medication or placebo (a tablet that looks like the investigation medication but has no active ingredients) in a tablet form, to be taken once a day for 32 weeks.

At the start of the study, participants will be randomly assigned to one of the two study drug groups. Participants within each study group will then be randomly assigned to receive either active study drug or a placebo.

Study-related examinations and health assessments will be performed at each study visit and participants will be asked to complete study daily bowel movement diaries.

All study medication or placebo and study-related examinations and procedures are provided at no cost. Qualified participants may be reimbursed for time and travel.

Who can participate?

To be eligible to participate in this study you must meet several criteria including the following: you are between 18 and 70 years of age, you have been diagnosed with ulcerative colitis, you are willing to complete participant assessments and attend scheduled clinical visits, and you satisfy all of the eligibility requirements.